Protective Effects of Remimazolam on Cerebral Ischemia/Reperfusion Injury in Rats by Inhibiting of NLRP3 Inflammasome-Dependent Pyroptosis

Min Shi,Jing Chen,Tianxiao Liu,Weixin Dai,Zhan Zhou,Lifei Chen,Yubo Xie

DOI: https://doi.org/10.2147/DDDT.S344240

2022-02-18

Abstract:Min Shi, &ast Jing Chen, &ast Tianxiao Liu, &ast Weixin Dai, Zhan Zhou, Lifei Chen, Yubo Xie Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yubo Xie, Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang-yong Road, Nanning, 530021, People's Republic of China, Tel +86 186 7795 8208, Email Introduction: Remimazolam is a novel benzodiazepine γ-aminobutyric acid A (GABAa) receptor agonist used for sedation and the induction as well as maintenance of general anesthesia. Previous research proved that anesthetic agents acting on GABAa receptor, such as thiopentone, propofol and midazolam, have protective actions for cerebral ischemia/reperfusion (I/R) injury. We here probed into remimazolam for its protective effect and potential mechanism of action against cerebral I/R injury. Material and Methods: A rat model of middle cerebral artery occlusion (MCAO) with focal transient cerebral I/R injury was established and was given tail vein injection of gradient remimazolam (5, 10, 20 mg/kg) after 2 h of ischemia. Following 24 h of reperfusion, neurological function, brain infarct volume, morphology of cerebral cortical neurons, and expressions of corticocerebral NLRP3, ASC, caspase-1, GSDMD, IL-1β and IL-18 were evaluated. Results: The results showed that remimazolam could effectively improve the neurological dysfunction, reduce the infarct volume and alleviate the damage of cortical neurons after I/R injury. Notably, the expression of NLRP3 inflammasome pathway was down-regulated, suggesting that remimazolam exerted protective actions on I/R injury by suppressing pyroptosis with decreased expression and release of inflammatory factors, and the involvement of the NLRP3 inflammasome pathway might be the core during that process. Overall, our results indicate that NLRP3 inflammation is a promising target. Conclusion: Based on this mechanism, remimazolam may be one of the ideal anesthetic drugs for patients with ischemic stroke. Keywords: remimazolam, NLRP3 inflammasome, ischemia/reperfusion injury, I/R, pyroptosis, inflammation Stroke is one of the primary causes of death in human with an annually increasing mortality. 1 In most cases, there is a need of surgery, such as stent implantation and cerebrovascular recanalization. 2 General anesthesia can contribute to lesser stress response and hemodynamics stability during surgery and has become the best choice for critical stroke. However, such management can be potentially risky for perioperative brain injury, 3 and the use of improper anesthetic agent may cause severe conditions. Given the fact, perioperative brain protection is always been a challenge in anesthesiologists and neurologists, and the selection of optimal anesthetic agent appears to be much more prominent. Archer et al 4 reported that general anesthesia by propofol, isoflurane and sevoflurane could alleviate the ischemic nerve injury in rodents of focal cerebral ischemia, yet the underlying mechanism was not clarified. In studies by Yang et al, 5 Peng et al, 6 Shi et al, 7 Liu et al 8 and Jiang et al 9 it was also found that the use of propofol, isoflurane, sevoflurane, midazolam and dexmedetomidine contributed to improved outcome of stroke with improved cerebral infarction and I/R injury. Inhaled anesthetics are rarely used for stroke due to the possible risk for increased intracranial pressure. Instead, intravenous anesthetics, such as propofol, dexmedetomidine and midazolam, are popular while with certain side effects which limit their use in clinic, for example, propofol has significant suppressive effect on circulation, dexmedetomidine is relatively poor in sedation and midazolam leads to a high incidence of delayed awakening from anesthesia. Remimazolam is a novel benzodiazepine agonist targeting γ-aminobutyric acid A (GABAa) receptor. It can stabilize hemodynamics while providing rapid anesthesia and awakening, and produce lesser suppressive effect toward breathing. In the meantime, it allows for prolonged infusions without accumulation and the metabolites have no any pharmacological action. Owing to the advantages, remimazolam is promising in clinical applications. 10,11 GABAergic signaling participates in multiple functions of macrophages, but the underlying mechanism has not been clarified yet. 12 It was reported that GABA receptor-associated protein, GABARAP, affected nucleotide-binding oligomerization domain‐like receptors pyrin domain containing 3 -Abstract Truncated-